Liquidia Corporation shares have soared 129.7% year to date, far outpacing the industry's 7% growth. The company's lead drug Yutrepia, an inhaled dry-powder treprostinil approved in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, generated approximately $130 million in sales in the first quarter of 2026. As of April 30, 2026, Yutrepia had received more than 4,500 unique patient prescriptions since its June 2025 launch, with about 3,750 patients initiating treatment and a prescription-to-start conversion rate of 85% or higher. The strong uptake helped Liquidia achieve its third consecutive profitable quarter, with net income reaching $52.9 million. The Zacks Consensus Estimate for 2026 earnings per share has risen to $3.02 from $1.50 over the past 60 days, and the stock currently trades at 7.95 times forward sales.
Liquidia Technologies IncStrong Yutrepia sales and patient uptake driving revenue and profitability
Johnson & Johnson
United Therapeutics Corporation